Real-world experience and analyses of the performance of ixekizumab as first-line biologic agent versus second-line (or higher) biologic agent in the treatment of chronic plaque psoriasis.

Int J Dermatol

Peterborough City Hospital, North West Anglia Foundation Trust (NWAFT), Peterborough, UK.

Published: August 2021

Download full-text PDF	Source
http://dx.doi.org/10.1111/ijd.15560	DOI Listing

Publication Analysis

biologic agent

real-world experience

experience analyses

analyses performance

performance ixekizumab

ixekizumab first-line

first-line biologic

agent versus

versus second-line

second-line higher

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!